LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance

U.S. Markets closed

Eli Lilly and Company (LLY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
67.85+0.66 (+0.98%)
At close: 4:00 PM EST

67.90 0.05 (0.07%)
After hours: 7:48 PM EST

People also watch:
BMYMRKABTGSKJNJ
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close67.19
Open0.00
Bid67.53 x 500
Ask67.90 x 300
Day's Range67.22 - 68.17
52 Week Range64.18 - 87.21
Volume4,350,764
Avg. Volume5,394,592
Market Cap71.6B
Beta0.13
PE Ratio (TTM)29.51
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.04 (3.03%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biogen Underplays Promising Alzheimer's Data On Seizure Worries
    Investor's Business Daily5 hours ago

    Biogen Underplays Promising Alzheimer's Data On Seizure Worries

    Biogen stock underplayed promising Alzheimer's Disease drug results on investor concern over a patient seizure.

  • Reuters7 hours ago

    New diabetes guidelines imminent, Jardiance sales may surge

    Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines reflecting the lifesaving cardiovascular effects of Eli Lilly's Jardiance in a move expected to drive up the drug's sales. The forthcoming guidelines from the American Diabetes Association and the American Association of Clinical Endocrinologists follow last Friday's decision by U.S. regulators to expand the health benefits Lilly can claim for Jardiance to include preventing fatal heart attacks and strokes in type 2 diabetes patients.

  • American City Business Journals8 hours ago

    Why the latest Alzheimer’s data is (mostly) great news for Biogen

    Shares of Biogen jumped Thursday afternoon when word leaked that its experimental Alzheimer’s drug, aducanumab, had performed well in an early-stage trial. By the time markets opened Friday morning, investor sentiment was clear: Biogen's aducanumab remains a frontrunner to become the first drug in the world to treat the underlying cause of Alzheimer’s, the sixth leading cause of death in the United States. As of 1 p.m., shares of Biogen (BIIB) were trading at $295.78, an increase of two percent that adds about $2 billion to the company’s market cap.